ストックスクリーナーアプリを入手
2.85
0.71%
0.02
アフターアワーズ：
2.80
-0.05
-1.75%
前日終値:
$2.83
開ける：
$2.8
24時間の取引高:
104.26K
Relative Volume:
0.30
時価総額：
$109.18M
収益：
$2.76M
当期純損益:
$-49.12M
株価収益率:
-1.90
EPS:
-1.5
ネットキャッシュフロー:
$-46.21M
1週間 パフォーマンス:
+4.78%
1か月 パフォーマンス:
+12.65%
6か月 パフォーマンス:
-49.38%
1年 パフォーマンス:
-57.27%
1日の値動き範囲:
$2.76
$2.88
1週間の範囲:
$2.7205
$3.0181
52週間の値動き範囲:
$2.37
$8.8699
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
名前
Orchestra Biomed Holdings Inc
セクター
電話
646-343-9298
住所
150 UNION SQUARE DRIVE, NEW HOPE
OBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
2.85 | 104.21M | 2.76M | -49.12M | -46.21M | -1.50 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-20 | 開始されました | BTIG Research | Buy |
| 2025-01-02 | 開始されました | Barclays | Overweight |
| 2024-08-22 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-25 | 開始されました | B. Riley Securities | Buy |
| 2024-01-19 | 開始されました | Jefferies | Buy |
| 2023-02-24 | 開始されました | Piper Sandler | Overweight |
| 2023-02-07 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Orchestra Biomed Holdings Inc (OBIO) 最新ニュース
B. Riley Cuts Price Target on Orchestra BioMed Holdings to $12 From $15, Keeps Buy Rating - marketscreener.com
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Stake Increased by Northern Trust Corp - Defense World
Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships - Seeking Alpha
Orchestra BioMed Reports Q1 2025 Financial Results and Advances Key Clinical Programs - MSN
How To Trade (OBIO) - news.stocktradersdaily.com
The Manufacturers Life Insurance Company Raises Position in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
FY2026 Earnings Estimate for OBIO Issued By Chardan Capital - Defense World
Orchestra BioMed Expands Patent Portfolio for AVIM Therapy, Gains FDA Breakthrough Designation - MSN
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates - MSN
Chardan Capital Maintains Buy Rating on OBIO with $20 Price Targ - GuruFocus
Barclays PLC Boosts Holdings in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
Wells Fargo & Company MN Buys 3,992 Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
Orchestra BioMed HoldingsBreakthrough Device Designation Gives Speculative Optimism - Seeking Alpha
Chardan Capital Maintains Buy Rating on OBIO with $20 Price Target | OBIO Stock News - GuruFocus
Orchestra BioMed (OBIO) Surpasses Revenue Estimates with Strong Q1 Growth | OBIO Stock News - GuruFocus
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones - The Manila Times
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy and IDE Approval for Virtue SAB Trial - Nasdaq
Orchestra BioMed Reports First Quarter 2025 Financial - GlobeNewswire
4 No-Brainer Stocks to Buy Right Now - The Globe and Mail
(OBIO) On The My Stocks Page - news.stocktradersdaily.com
Orchestra BioMed receives FDA approval to initiate Virtue Trial - Med-Tech Insights
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Shares Sold by Price T Rowe Associates Inc. MD - The AM Reporter
RTW INVESTMENTS, LP Increases Stake in Orchestra BioMed Holdings Inc - GuruFocus
ORCHESTRA BIOMED Earnings Preview: Recent $OBIO Insider Trading, Hedge Fund Activity, and More - Nasdaq
Orchestra BioMed’s AVIM Therapy Global Intellectual - GlobeNewswire
Orchestra BioMed (OBIO) Expands Patent Portfolio for AVIM Therap - GuruFocus
Orchestra BioMed Expands Patent Portfolio with 10 New Patents for Hypertension Treatment, Totaling 120 Global Patents - Nasdaq
Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure - GlobeNewswire
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - MSN
BlackRock, Inc. Reduces Stake in Orchestra BioMed Holdings Inc. - GuruFocus
Orchestra BioMed (NASDAQ:OBIO) Price Target Lowered to $12.00 at Barclays - Defense World
Orchestra BioMed Holdings (OBIO) Target Price Adjustment by Barc - GuruFocus
Barclays Adjusts Price Target for Orchestra BioMed (OBIO) | OBIO Stock News - GuruFocus
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Shares Bought by JPMorgan Chase & Co. - Defense World
OBIO: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
How did Orchestra BioMed Holdings Inc (OBIO) fare last session? - uspostnews.com
Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment - MyChesCo
Orchestra Biomed sees $149,201 stock purchase by RTW Investments By Investing.com - Investing.com Australia
Orchestra BioMed Holdings Inc [OBIO] Records 200-Day SMA of $5.25 - knoxdaily.com
Orchestra BioMed to Present at Jefferies Global Healthcare Conference - MyChesCo
Geode Capital Management LLC Boosts Stock Holdings in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
FDA approves head-to-head trial of Orchestra BioMed’s balloon - Investing.com
Orchestra BioMed (OBIO) Gains FDA Nod for Updated Coronary ISR T - GuruFocus
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy - Diagnostic and Interventional Cardiology
FDA Clears Orchestra BioMed's Virtue SAB Trial To Treat Coronary ISR - Nasdaq
Orchestra Biomed Holdings Inc (OBIO) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):